Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Renalytix Ai Plc ADR (NQ: RNLX ) 0.2071 UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Renalytix Ai Plc ADR < Previous 1 2 Next > Commencement of trading on OTCQB in the United States October 08, 2024 Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 From Renalytix plc Via GlobeNewswire Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US July 11, 2024 From Renalytix plc Via GlobeNewswire Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination June 27, 2024 Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” From Renalytix plc Via GlobeNewswire Renalytix PLC (NASDAQ: RNLX) Near the Top of Equities by Percentage Gain on 6/30 June 30, 2023 Via Investor Brand Network Medicare Issues Final Coverage Determination for kidneyintelX.dkd June 14, 2024 Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage From Renalytix plc Via GlobeNewswire Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 May 15, 2024 From Renalytix plc Via GlobeNewswire Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15 May 09, 2024 From Renalytix plc Via GlobeNewswire Renalytix Announces Financing with Expected Size of up to $4 Million April 08, 2024 From Renalytix plc Via GlobeNewswire KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD) March 14, 2024 Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk From Renalytix plc Via GlobeNewswire Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024 February 15, 2024 From Renalytix plc Via GlobeNewswire Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 09, 2024 From Renalytix plc Via GlobeNewswire New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease January 10, 2024 From Renalytix plc Via GlobeNewswire Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 November 14, 2023 From Renalytix plc Via GlobeNewswire Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14 November 07, 2023 From Renalytix plc Via GlobeNewswire US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix October 06, 2023 From Renalytix plc Via GlobeNewswire Renalytix Reports Full Year Fiscal 2023 Results September 28, 2023 From Renalytix plc Via GlobeNewswire Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28 September 25, 2023 From Renalytix plc Via GlobeNewswire Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer September 07, 2023 Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort From Renalytix plc Via GlobeNewswire Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd August 03, 2023 World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease From Renalytix plc Via GlobeNewswire Renalytix Announces Middle East Distribution Agreement with Vector Pharma July 21, 2023 From Renalytix plc Via GlobeNewswire Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions July 07, 2023 From Renalytix plc Via GlobeNewswire Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors July 03, 2023 From Renalytix plc Via GlobeNewswire FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease June 29, 2023 From Renalytix plc Via GlobeNewswire Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 June 09, 2023 From Renalytix plc Via GlobeNewswire Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 June 05, 2023 From Renalytix plc Via GlobeNewswire Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes May 25, 2023 Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage From Renalytix plc Via GlobeNewswire New Published Real-World Evidence Shows KidneyIntelX™ Utility April 19, 2023 From Renalytix plc Via GlobeNewswire Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting April 12, 2023 From Renalytix plc Via GlobeNewswire Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results March 30, 2023 From Renalytix plc Via GlobeNewswire Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30 March 22, 2023 From Renalytix plc Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
